BPC-157 Arginate

Mechanism

BPC-157 Arginate shares the same mechanism as the parent compound BPC-157. The peptide modulates multiple healing pathways: it upregulates VEGFR2 and eNOS to promote angiogenesis (new blood vessel formation), stimulates fibroblast and tendon cell proliferation, modulates the nitric oxide system, and demonstrates anti-inflammatory effects through cytokine regulation. It also interacts with the dopamine and serotonin systems in the brain, which may underlie its observed neuroprotective effects. The arginate counterion does not alter these mechanisms but improves the peptide's physicochemical stability in solution.

Evidence base

Evidence Grade: Limited

The BPC-157 literature comprises over 100 peer-reviewed preclinical studies, predominantly from animal models. Key findings include accelerated healing of tendons, ligaments, muscle, bone, gastric mucosa, and skin. However, the evidence base has notable limitations:

• No published large-scale human clinical trials as of 2025.
• A significant proportion of publications originate from a single Croatian research group (Sikirić et al.), raising questions about independent replication.
• Most studies use rodent models with dose extrapolation challenges for human application.
• The arginate salt form has been characterised primarily for stability and formulation properties, with limited direct pharmacological comparison to the free base.

Researchers should treat the preclinical findings as hypothesis-generating rather than confirmed efficacy in humans.

Protocols

Research protocols discussed in the community typically reference 250–500 mcg per administration, 1–2 times daily, for 2–4 week cycles. These are extrapolated from animal studies and have not been validated in human trials. The arginate salt form may offer advantages for oral administration research due to improved stability, though oral bioavailability data is limited. Subcutaneous injection remains the most discussed route. This is not medical advice.

UK legal status

BPC-157 Arginate is not a licensed medicine in the UK and is not MHRA-approved for human therapeutic use. It is legal to purchase and possess for legitimate research purposes. Selling BPC-157 products for human consumption would be an offence under MHRA regulations. Researchers should source from suppliers that clearly label products 'for research use only' and provide certificates of analysis.

Vendor notes

Look for vendors that supply third-party COAs confirming peptide identity and purity (≥98%). The arginate salt form should be specified on the COA. Verify storage and shipping conditions, as peptide integrity depends on temperature control.